NCT06591767View on ClinicalTrials.gov

Quercetin as Possible Supportive Therapy for Mild to Moderate Hyperuricemia

NACompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

October 1, 2023

Primary Completion Date

April 30, 2024

Study Completion Date

August 31, 2024

Conditions
Hyperuricemia
Interventions
DIETARY_SUPPLEMENT

Quercetin

200 mg supplemental Quercefit®

COMBINATION_PRODUCT

Berberol K®

"Berberine Phytosome® 730 mg~\+ MonakoPure® containing 2.9 mg of monacolin K and KA from red yeast rice extract"

Trial Locations (1)

Unknown

S. Orsola-Malpighi Polyclinic Hospital, Bologna

All Listed Sponsors
collaborator

"University of Urbino Carlo Bo"

OTHER

lead

Liaquat University of Medical & Health Sciences

OTHER

NCT06591767 - Quercetin as Possible Supportive Therapy for Mild to Moderate Hyperuricemia | Biotech Hunter | Biotech Hunter